Cypherpunk Technologies names Amanda Fabiano to board of directors
The privacy technology company disclosed the appointment in an 8-K filed September 22, 2026, alongside details on its Zcash mining operation and treasury.
Cypherpunk Technologies Inc. (Nasdaq: CYPH) said on September 22, 2026 that its board had appointed Amanda Fabiano as a director. The board named Fabiano to serve as a Class III director, effective immediately.1 She is set to serve until the 2029 Annual Meeting of Stockholders, or until she resigns, dies, or is removed earlier.1 The company said Fabiano has not yet been assigned to any board committees.1
Fabiano's other current roles include work at bitcoin-related companies. She holds the position of Chief Operating Officer at Nakamoto Inc., which the filing describes as a publicly listed bitcoin-focused company, and she also sits as an independent director at TeraWulf Inc., described as a public bitcoin mining company that has grown into AI and high-performance computing infrastructure.1 Earlier in her career she held senior mining and investment positions at Galaxy and Fidelity, where the company said she contributed to some of the earliest institutional digital asset mining programs.1
On compensation, Fabiano will receive restricted stock unit awards for 250,000 shares total, split between a 150,000-share initial grant that vests in annual installments over three years and an annual grant tied to service through the 2027 Annual Meeting in June 2027, which vests at that meeting.1 The company and Fabiano also signed a director and officer indemnification agreement dated September 22, 2026.1
The announcement followed operational updates on Cypherpunk's crypto mining business. Fabiano's appointment came after the company's August launch of Cypherpunk Mining, which deployed approximately 4.2 GSol/s of hashrate across the United States.1 Between August 18 and August 31, 2026, that operation generated 3,023.13 ZEC in mining rewards, all added to the corporate treasury.1 The filing also noted that through its subsidiary Leap Therapeutics, the company is developing cancer therapies sirexatamab and FL-501.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.